Robert Moore
Optometrist · Tuscaloosa, ALNPI 1487618674
Payments from drug & device makers
Across 105 payments — averaging $41.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Johnson & Johnson Vision Care, Inc.$587
- NEW World Medical,inc.$363
- AbbVie$348
- Bausch & Lomb Americas Inc.$248
- Biotissue Holdings Inc.$240
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,21296%
- Entertainment$1644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 17 | $1,211 |
| Johnson & Johnson Vision Care, Inc. | 28 | $587 |
| NEW World Medical,inc. | 3 | $363 |
| AbbVie(2 entities) | 19 | $348 |
| Bausch & Lomb Americas Inc. | 10 | $248 |
| Biotissue Holdings Inc. | 3 | $240 |
| Glaukos Corporation | 2 | $222 |
| Novartis | 4 | $173 |
| Optos, Inc. | 1 | $164 |
| Astellas Pharma US Inc | 2 | $160 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $120 |
| Avedro Inc. | 1 | $107 |
| Dompe US, Inc. | 1 | $87 |
| Sight Sciences, Inc. | 1 | $82 |
| Sun Pharmaceutical Industries Inc. | 2 | $54 |
| Hu-friedy Mfg. Co., LLC | 1 | $43 |
| Thea Pharma Inc. | 2 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $31 |
| Harrow Eye, LLC | 1 | $29 |
| Coopervision Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$328
- OCT OPHTHALMOSCOPE$328
- Kahook Dual Blade$267
- Ahmed Glaucoma Valve$267
- AcrySof IQ VIVITY IOL$238
- NFC-700$164
- Clearpath$138
- Streamline$138
- Via360$138
- Streamline Surgical System$130
- Clareon$127
- AcrySof IQ VIVITY$126
- XIIDRA$125
- Precision7$123
- Centurion$121
- iStent inject Trabecular Micro-Bypass Stent System$120
- AcrySof IQ PanOptix$103
- KXL System$102
- Photrexa$102
How this compares
$4,376 in reported general payments places this provider in the 90th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 79 | $71,004 |
| XiidraLifitegrast | 40 | $32,616 |
| LumiganBimatoprost | 84 | $30,440 |
| VevyeCyclosporine | 16 | $17,391 |
| Cyclosporine | 45 | $14,886 |
| VyzultaLatanoprostene Bunod | 44 | $13,771 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $9,669 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $5,267 |
| IyuzehLatanoprost/Pf | 15 | $4,974 |
| Travoprost | 19 | $4,706 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,519 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 130 | $3,122 |
| Timolol Maleate | 18 | $2,962 |
| Latanoprost | 154 | $1,837 |
| Loteprednol Etabonate | 13 | $1,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $348 | $111,113187 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $248 | $46,38884 claims |
| Harrow Eye, LLCVevye | $29 | $17,39116 claims |
| Thea Pharma Inc.Iyuzeh | $41 | $4,97415 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $36 | $4,51914 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $31 | $1,64613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 749 optometrist providers in Alabama.
Other optometrist in Tuscaloosa
- Andrew PuckerBirmingham$667K
- Mark SchaefferHoover$473K
- Kelly NicholsBirmingham$298K
- Benjamin KachelmanFlorence$102K
- Natalie WestBirmingham$85K
- Katherine WeiseBirmingham$82K
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Jack SchaefferHoover$60K
- Leo SemesBirmingham$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.